E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Tudriqev is approved for use in combination with nivolumab to treat adults with unresectable advanced cutaneous melanoma after progression on an anti-PD-1-based regimen.
imphoenix82
Under a licensing agreement signed with Philogen in May 2023, Sun Pharma holds exclusive commercialization rights for Nidlegy in Europe, Australia and New Zealand for the treatment of skin cancers.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
